Principal Technologies (FRA:JO7) PEG Ratio: N/A (As of Jul. 03, 2026)


FRA:JO7 Principal Technologies Inc FRA:JO7
1 GF Score
Price €0.20
GF Value €0.02
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Principal Technologies PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Principal Technologies's PE Ratio without NRI is 0.00. Principal Technologies's 5-Year EBITDA growth rate is -73.60%. Therefore, Principal Technologies's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Principal Technologies's PEG Ratio or its related term are showing as below:



FRA:JO7's PEG Ratio is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.41
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Principal Technologies  (FRA:JO7) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Principal Technologies PEG Ratio Related Terms


Principal Technologies PEG Ratio Historical Data

* Premium members only.

The historical data trend for Principal Technologies's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Principal Technologies PEG Ratio Chart

Principal Technologies Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
PEG Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Principal Technologies Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:JO7 vs VEEV, BTSG, TEM: PEG Ratio Comparison

For the Health Information Services subindustry, Principal Technologies's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Principal Technologies PEG Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Principal Technologies's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Principal Technologies's PEG Ratio falls into.


FRA:JO7
1GF Score
Principal Technologies Inc FRA:JO7
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Principal Technologies PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Principal Technologies's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/-73.60
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Principal Technologies (FRA:JO7) Overvalued in 2026?

Based on GuruFocus' analysis, Principal Technologies stock appears to be overvalued. The current stock price of €0.20 is trading 875% above its estimated GF Value™ of €0.02. GuruFocus considers Principal Technologies to be Significantly Overvalued.

Key valuation signals for FRA:JO7:

  • PEG Ratio: N/A
  • GF Value™: €0.02 vs. price of €0.20 (875% above fair value)
  • GF Score™: 1/100 with 7 warning signs

No single metric tells the full story. See the FRA:JO7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Principal Technologies Business Description

Other Exchanges PTEC:Canada
Address 700 West Georgia Street, Suite 2500, Vancouver, BC, CAN, V7Y 1B3
Principal Technologies Inc is in the research and development stage of building a portfolio of medical technology assets with a focus on distribution potential and intellectual property capable of enhancing medical treatment, cost efficiency, and optimization of the patient pathway. The company focuses on acquiring medical technology research and development assets or developing them jointly with industry leaders. Its current revenue-generating activities are attributable to E&E CRO Consulting GmbH, which provides clinical research advisory services. The company operates in one reportable operational segment, consisting of project management of clinical studies and research related to medical device technologies.
1GF Score

Get the complete analysis for FRA:JO7

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€0.02
GF Value